Literature DB >> 20697684

[Cold-induced urticaria and angioedema. Classification, diagnosis and therapy].

K Krause1, F Degener, S Altrichter, E Ardelean, D Kalogeromitros, M Magerl, M Metz, F Siebenhaar, K Weller, M Maurer.   

Abstract

The onset of wheals and/or angioedema following the exposure to cold may be associated with a number of different diseases. Most frequently this occurs in cold contact urticaria, a type of physical urticaria, which is characterized by a positive cold stimulation test. The clinical symptoms are based on cold-dependent mast cell activation with subsequent release of proinflammatory mediators. In cases of negative or atypical reaction to cold stimulation testing rare acquired atypical or familiar cold urticaria forms may be suspected. Strict avoidance of cold should be recommended as far as possible. As the underlying causes of cold contact urticaria are widely unknown, the symptomatic use of non-sedating antihistamines is the treatment of first choice. The very rare familiar cold auto-inflammatory syndrome (FCAS) is based on CIAS1/NLRP3 mutations and may be treated effectively by neutralization of pathogenic interleukin 1beta.

Entities:  

Mesh:

Year:  2010        PMID: 20697684     DOI: 10.1007/s00105-010-1932-9

Source DB:  PubMed          Journal:  Hautarzt        ISSN: 0017-8470            Impact factor:   0.751


  57 in total

1.  Delayed cold urticaria.

Authors:  C N Matthews; R P Warin
Journal:  Br J Dermatol       Date:  1977-07       Impact factor: 9.302

2.  [Epidemiology and clinical aspects of cold urticaria].

Authors:  A Möller; M Henning; T Zuberbier; B M Czarnetzki-Henz
Journal:  Hautarzt       Date:  1996-07       Impact factor: 0.751

3.  Anti-immunoglobulin E treatment of patients with recalcitrant physical urticaria.

Authors:  Martin Metz; Sabine Altrichter; Elena Ardelean; Birgit Kessler; Karoline Krause; Markus Magerl; Frank Siebenhaar; Karsten Weller; Torsten Zuberbier; Marcus Maurer
Journal:  Int Arch Allergy Immunol       Date:  2010-08-24       Impact factor: 2.749

4.  Efficacy and safety of rilonacept (interleukin-1 Trap) in patients with cryopyrin-associated periodic syndromes: results from two sequential placebo-controlled studies.

Authors:  Hal M Hoffman; Martin L Throne; N J Amar; Mohamed Sebai; Alan J Kivitz; Arthur Kavanaugh; Steven P Weinstein; Pavel Belomestnov; George D Yancopoulos; Neil Stahl; Scott J Mellis
Journal:  Arthritis Rheum       Date:  2008-08

5.  Use of canakinumab in the cryopyrin-associated periodic syndrome.

Authors:  Helen J Lachmann; Isabelle Kone-Paut; Jasmin B Kuemmerle-Deschner; Kieron S Leslie; Eric Hachulla; Pierre Quartier; Xavier Gitton; Albert Widmer; Neha Patel; Philip N Hawkins
Journal:  N Engl J Med       Date:  2009-06-04       Impact factor: 91.245

6.  Tumor necrosis factor-alpha release during systemic reaction in cold urticaria.

Authors:  I Tillie-Leblond; P Gosset; A Janin; R Dalenne; M Joseph; B Wallaert; A B Tonnel
Journal:  J Allergy Clin Immunol       Date:  1994-02       Impact factor: 10.793

7.  [Urticaria caused by cold. 104 cases].

Authors:  M C Koeppel; S Bertrand; R Abitan; R Signoret; J Sayag
Journal:  Ann Dermatol Venereol       Date:  1996       Impact factor: 0.777

8.  Clinical features and natural history of acquired cold urticaria in a tertiary referral hospital: a 10-year prospective study.

Authors:  A Katsarou-Katsari; M Makris; E Lagogianni; S Gregoriou; T Theoharides; D Kalogeromitros
Journal:  J Eur Acad Dermatol Venereol       Date:  2008-12       Impact factor: 6.166

9.  Acquired cold urticaria symptoms can be safely prevented by ebastine.

Authors:  M Magerl; J Schmolke; F Siebenhaar; T Zuberbier; M Metz; M Maurer
Journal:  Allergy       Date:  2007-09-26       Impact factor: 13.146

10.  Human in vivo cutaneous microdialysis: estimation of histamine release in cold urticaria.

Authors:  T Andersson; K Wårdell; C Anderson
Journal:  Acta Derm Venereol       Date:  1995-09       Impact factor: 4.437

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.